Expediency of the determination of S100, CD44 oncomarkers in patients with suspected melanoma in cases of complex differential diagnosis
https://doi.org/10.25694/URMJ.2018.04.077
Abstract
To date, a number of specific proteins have been proposed as markers for the diagnosis of melanoma, S100 and sCD44std are among them. The aim of the study was to determine the diagnostic value of these oncomarkers in the blood serum of patients in complex cases of differential diagnosis of skin melanoma. The serum for S100 and sCD44std proteins was studied in 24 patients with melanocytic neoplasms of the skin. When assessing the sensitivity, specificity and diagnostic accuracy, it was established that for the differential diagnosis of skin melanoma, these indicators were 16.7%, 88.89% and 70.83%, respectively. Thus, the currently proposed oncomarkers for the diagnosis of skin melanoma do not have sufficient diagnostic value necessary for the detection of skin melanoma. The inclusion of a serum study on S100 and sCD44std proteins in a diagnostic algorithm in cases of complex differential diagnosis of melanocytic neoplasms of the skin is not advisable.
References
1. Palmer S.R., Erickson L.A., Ichetovkin I. et al. Circulating serologic and molecular biomarkers in malignant melanoma. // Mayo clinic proceedings. 2011, Т. 86(10), p. 981-90.
2. Sabel M.S., Liu Y., Lubman DM. Proteomics in melanoma biomarker discovery: great potential, many obstacles. // International journal of proteomics. 2011; 2011: 181890. doi: 10.1155/2011/181890. Epub 2011 Oct 11.
3. Rothberg B.E., Moeder C.B., Kluger H. et al. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. // Modern pathology. 2008, T21(9), p. 1121-9.
4. Utikal J., Schadendorf D., Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. // Archives of dermatological research. 2007, T 298 (10), p. 469-77.
5. Gogas H., Eggermont A.M., Hauschild A et al. Biomarkers in melanoma. // Annals of oncology. 2009, Suppl 6: vi8-13. doi: 10.1093/annonc/mdp251.
6. Liu S., Kirschmeier P., Simon J et al. Prognostic and predictive molecular markers in cutaneous malignant melanoma: the first step toward personalized medicine. //Current Pharmacogenomics and Personalized Medicine. 2008 z, Т. 6, 4, p 272-94.
7. Available at: https://www.rusmedserv.com/files/labdiag/25_onkomarkery.pdf
8. Karjalainen J.M., Tammi R.H., Eskelinen M.J. et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. // American Journal of Pathology. 2000., Т. 157 (3), p. 957-65. SyM. S., Mori H., Liu D. CD44 as a marker in human cancers. // Current Opinion in Oncology. 1997, Т. 9(1), p. 108-12.
Review
For citations:
Sokolova AV. Expediency of the determination of S100, CD44 oncomarkers in patients with suspected melanoma in cases of complex differential diagnosis. Ural Medical Journal. 2018;(5):119-121. (In Russ.) https://doi.org/10.25694/URMJ.2018.04.077
Views:
267
Email this article 